Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01797523 · ClinicalTrials.gov registry record · Phase 2

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

A Phase 2 study of Endometrial Cancer, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
62
Enrollment target
6
Study locations

NCT01797523 is a Phase 2 study of Endometrial Cancer that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 62 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (88% lower). The trial reports 6 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01797523, a Phase 2 study of Endometrial Cancer, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
62 participants
Enrollment target
6
Study locations

Study Summary

The goal of this clinical research study is to learn if the combination of everolimus, letrozole, and metformin can help to control recurrent or progressive endometrial cancer. The safety of this drug combination will also be studied. Everolimus is designed to block a protein inside cancer cells that is involved in cancer growth. Letrozole is designed to block a protein from making estrogen. This may interfere with the growth of cancer cells. Metformin is commonly used to control blood sugar levels in patients with diabetes. It is designed to lower insulin levels, which may slow or stop the growth of endometrial cancer cells.

Conditions Studied

Endometrial Cancer

Interventions

  • DRUG Letrozole
  • DRUG Everolimus
  • DRUG Metformin

Study Locations (6)

Texas

  • Memorial City Medical Center - Houston
  • Lyndon B Johnson General Hospital - Houston
  • University of Texas MD Anderson Cancer Center - Houston
  • The Woman's Hospital of Texas - Houston

Florida

  • Sacred Heart Health Systems - Pensacola

New Jersey

  • MD Anderson Cooper Cancer Center - Voorhees Township

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2013-10-07
Est. Completion 2027-10-31
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01797523

The ClinicalTrials.gov registry entry for NCT01797523 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (88% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 3 interventions - of which Letrozole is the first listed.

NCT01797523 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Texas, Florida, New Jersey.

Frequently Asked Questions

What is clinical trial NCT01797523 about?

NCT01797523 is a clinical study titled "A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma". The goal of this clinical research study is to learn if the combination of everolimus, letrozole, and metformin can help to control recurrent or progressive endometrial cancer. The safety of this drug combination will also be studied. Everolimus is designed to block a protein inside cancer cells th...

What is the current status of trial NCT01797523?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2013-10-07. Estimated completion is 2027-10-31.

What conditions does trial NCT01797523 study?

This clinical trial studies the following conditions: Endometrial Cancer.

What interventions are being tested in trial NCT01797523?

The interventions under investigation include: Letrozole (DRUG), Everolimus (DRUG), Metformin (DRUG).

Who is sponsoring clinical trial NCT01797523?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01797523 being conducted?

This trial has 6 study locations across Florida, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Endometrial Cancer

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.